Search for the best prices     on the Internet!

Table of Contents:

List of Editors and principal contributors
Foreword
1 Sexual health in the aging male 3
2 Determinants of sexual function in the aging male 11
3 Impact of radical prostatectomy and primary radiotherapy for localized prostate cancer on quality of life 14
4 Sexual function before and after radical retropubic prostatectomy: a prospective analysis 22
5 Effects of endocrine treatment: can libido and sexual function be preserved? 27
6 Oral therapy 41
7 Intracavernosal injection therapy for erectile dysfunction: an update 49
8 Mechanisms and prevention of erectile dysfunction after radiotherapy for prostate cancer 65
9 Evaluation and management of lower urinary tract symptoms as related to benign prostate disease: the contribution of the International Continence Society - 'Benign Prostatic Hyperplasia' study 71
10 Distinguishing nocturnal polyuria from benign prostatic hyperplasia-related nocturia: simple algorithms for general and urological practice 82
11 Practical application of non-invasive tests to grade outflow obstruction and bladder contractility: the end of classical urodynamics? 88
12 Screening for prostate cancer within the benign prostatic hypertrophy population: current evidence and future directions 98
13 Androgen supplementation in older men: what is the impact on prostate-specific antigen, prostate growth and lower urinary tract symptoms? 111
14 Diagnosis, classification and therapy development for human prostate cancer using biochip technologies and post-genomic era molecular medicine 123
15 Candidate genetic markers and therapeutic targets in hereditary and sporadic prostate cancer 128
16 Basic research on prostate cancer: signal transduction 136
17 Stem cells and differentiation in human prostate cancer 145
18 Role of the stromal microenvironment in carcinogenesis of the prostate 155
19 Prostate cancer xenograft models 172
20 Hormonal regulation of prostate cancer 180
21 Profiling protein interactions in angiogenesis 187
22 The immunotherapy of prostate cancer 191
23 Prognostic tissue factors for prostate cancer: recent developments and pitfalls 195
24 Diagnostic markers for prostate cancer detected in serum, plasma or blood: prostate-specific antigen forms and human kallikrein 2 for early detection and staging 206
25 Expected impact of new technologies on prostate cancer research 222
26 Predictive algorithms and their clinical relevance 230
27 Defining the proper 'window of opportunity' in the early detection of prostate cancer 239
28 Screening for prostate cancer: views from the UK and the rest of the world 248
29 Outcome after radical prostatectomy: how predictive are biopsies versus radical prostatectomy specimens? 256
30 A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer 262
31 Prostate cancer mortality and screening 267
32 Expectant management with selective delayed intervention for favorable-risk prostate cancer 274
33 Is cure of prostate cancer possible in those in whom it is necessary? 280
34 Modern molecular classification of renal cell carcinoma: relevance for urologists 286
35 Prognostic factors for renal cell carcinoma 291
36 High-tech diagnostic procedures in renal cell carcinoma: promise and practice 304
37 Technical and surgical process in organ-sparing approaches for renal cell carcinoma 310
38 Surgery for renal cell carcinoma: the case for open surgery 319
39 Laparoscopic partial nephrectomy 323
40 Laparoscopic radical nephrectomy 332
41 Clinical research avenues in metastatic renal cell carcinoma 339
42 Diet and prostate cancer 350
43 Determinants of prostate cancer-specific survival following radiation therapy for patients with clinically localized prostate cancer 380
44 Use of adjuvant hormonal therapy with radical prostatectomy in lymph node-positive disease: rationale and contribution to outcome 390
45 Side-effects of endocrine treatment: role of duration treatment 400
46 Chemotherapy for the treatment of hormone-refractory prostate cancer: evaluating new targets based on apoptotic pathways 407
47 The role of biphosphonates in prostate cancer 414
48 Direct from the pipeline: results of phase I and II studies of new drugs 421
49 Chemotherapy in the management of prostate cancer 436
Index 436